PRIMARY STUDY
Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin
Key Findings: Resulting data suggests that the liquid oral use of CBDV (600mg) can modulate atypical striatal circuitry towards neurotypical function in this patient population.
Type of Study: Double Blind Clinical Trial
Study Result: Positive
Research Location(s): Germany, Netherlands, Spain, United Kingdom
Year of Pub: 2021
Cannabinoids Studied: Cannabinoid (unspecified), Cannabidivarin (CBDV)
Phytocannabinoid Source: Unspecified
Dosage: 600 mg
Route of Administration: Oral (Ingestion)
Citation: Pretzsch CM, et al. Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin. Mol Autism. 2021; 12:49. doi: 10.1186/s13229-021-00454-6
Authors: Pretzsch CM, Floris DL, Voinescu B, Elsahib M, Mendez MA, Wichers R, Ajram L, Ivin G, Heasman M, Pretzsch E, Williams S, Murphy DGM, Daly E, McAlonan GM
